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Abstract  
Pyrimidine-5-carbaldehyde derivatives, of easy access, were selected as precursors for the 
synthesis of mimic pteridine derivatives 5,6-dihydropyrimido[4,5-d]pyrimidines and 5,6,7,8-
tetrahydropyrimido[4,5-d]pyrimidines via 4-amino-(5-aminomethyl)pyrimidine intermediates. 
Straightforward procedures allow a quick access to these compounds. The dihydro derivatives 
were prepared means of a final cyclocondensation carried out with orthoesters, catalysed by acid 
and assisted by microwaves irradiation under solvent free conditions. The final cyclo-
condensation with carbonyl compounds forming the tetrahydro derivatives was done under mild 
conditions, in which stereochemical induction was carried out on the building of this skeleton, 
and stereochemistry assignments corroborated by theoretical calculations. 
 
Keywords:  4-Amino-5-(aminomethyl)pyrimidines; microwave irradiation; theoretical 
calculations; acid catalysis; cyclocondensation; stereoselectivity 
 
 
 
Introduction 
 
Pyrimidine-fused compounds are of interest in medicinal chemistry and chemical biology due to 
their wide range of biological activities.1-4 See Figure 1 for compounds with the pyrimido[4,5-d]-
pyrimidine scaffold that have been found to show pharmacological activity, such as antiplatelet,5 
tyrosine kinase inhibitor,6-8 antifolate (I-II),9 antibacterial (III-IV),10,11 anti-inflammatory,12 
hepatoprotective (V)13 and antiviral14 properties. 
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Figure 1. Some pyrimido[4,5-d]pyrimidine derivatives with diverse biological properties. 
 
On account of the pharmaceutical interest in these compounds, the development of high-
throughput methodologies for the synthesis of novel pyrimidine-fused heterocyclic scaffolds is in 
continuous expansion.15-19 It has become widely accepted that many classical reactions perform 
better under microwave irradiation than by conventional heating methods.20-24 Microwave 
irradiation has been used to carry out a wide range of reactions in short times, with high yields 
and regioselectivity, and frequently without the need of solvents.25 
With the aim to tune up simple reaction methodologies, we have focused our strategy in the 
use of 4-aminopyrimidine-5-carbaldehydes as key precursors for the preparation of cited fused 
heterocyclic system (see Figure 2) because they have the appropriate spatial arrangement of 
atoms. We have previously reported some 4-aminopyrimidine-5-carbaldehydes and employed 
them for the preparation of pyridopyrimidine derivatives.26 
 
 
 
Figure 2 
 
We here present the synthesis of a new series of 5,6-dihydro and 5,6,7,8-tetrahydro 
derivatives by a three step process starting from the corresponding 4-aminopyrimidines, via 
formation of 4-amino-(5-aminomethyl)pyrimidines as intermediates for further 
cyclocondensation with orthoesters and carbonyl compounds respectively. 
In the tetrahydropyrimido[4,5-d]pyrimidines a stereogenic center is generated and the 
experimental conditions to induce stereoselectivity are discussed below.  
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Results and Discussion 
 
The key precursor 6-aminopyrimidin-4(3H)-one-5-carbaldehydes, 1a,b, were prepared by 
Vilsmeier-Haack formylation of 6-aminopyrimidin-4(3H)-ones VI,26 and then reaction with 
various primary amines, such as aniline, benzylamine and cyclohexylamine, in order to get the 
required diamino intermediate 2 for further cyclocondensation via reaction with the carbaldehyde 
group. The standard reductive reagents and conditions were tested in order to afford compounds 
2, but just the use of sodium triacetoxyborohydride in THF was effective to perform the one step 
amino reduction. The reaction workup is simple and straightforward, and compounds 2 were 
isolated by filtration in good to excellent yields (Scheme 1 and Table 1). 
 
 
 
Scheme 1. Synthetic route to pyrimidopyrimidines 3 from aminopyrimidines. 
 
Table 1. Data for the synthesis of 2a-g shown in Scheme 1 
Entry X R1 
Compounds 2 
Yield (%) Mp ºC 
2a O C6H5 98 250 
2b O CH2C6H5 82 125 
2c O C6H11 80 210 
2d S C6H5 92 175 
2e S CH2C6H5 78 118 
2f S C6H11 90 140 
2g/g′  S CH(CH3)C6H5 86/81 - 
 
Compounds 2 were fully characterized by spectroscopic and analytical data. From the 
spectroscopic data of compounds 2, the disappearance of signals corresponding to the 
carbaldehyde in 1, and the appearance of the derived methylene group and the signals which 
correspond to the amine residue, are clearly observed. In the case of 2a, the signal for 5-CH2 is 
observed at 3.95 ppm (as a doublet, coupled with NH) and at 37.0 ppm, in the 1H- and 13C-NMR 
spectra respectively.  
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For the cyclocondensation of the diamine derivative 2, we first tried several acid derivatives 
such as acyl chlorides and anhydrides, and different conditions, but with no positive results. 
Finally we chose orthoesters, which provided the corresponding 5,6-dihydropyrimido[4,5-d]-
pyrimidin-4(3H)-ones 3, in satisfactory yields.  
According to the literature, reactions with this kind of reagent need drastic conditions.27,28 An 
attempt to carry out these reactions by conventional heating gave decomposition of starting 
material because of the long reaction times required. To avoid conventional heating, we chose to 
assist the reaction with microwave irradiation, and we found that the reaction took place at 200 
ºC over 10–15 minutes with orthoester in excess (three- and four-fold molar) and in the absence 
of solvent to yield the desired pyrimidopyrimidines 3, but not in good yields (< 45 %). This was 
probably due to the partial decomposition of the products under such conditions. From the 
different acid catalysts screened to optimize the reaction conditions, acetic acid was found to 
give the best results. After addition of acetic acid the reactions were greatly improved: the 
reaction time fell to 1 minute, the temperature for the reaction dropped to 150 ºC, and yields 
were considerably increased (Table 2). Nevertheless no useful results were obtained when the 6-
amino-5-(phenylaminomethyl)pyrimidin-4-one 2a was taken as starting material. 
 
Table 2. Data for the reaction of 2 with orthoesters to products 3a-i with AcOH as catalyst (see 
Scheme 1) 
Entry X R1 R2 
Compounds 3 
Yield (%) Mp ºC 
3a O CH2C6H5 H 65 178 
3b O CH2C6H5 CH3 49 142 
3c O C6H11 H 80 227 
3d S C6H5 H 75 174 
3e S C6H5 CH3 60 146 
3f S CH2C6H5 H 70 126 
3g S CH2C6H5 CH3 67 115 
3h S C6H11 H 69 189 
3i S C6H11 CH3 53 237 
 
Compounds 3 were fully characterized by spectroscopic and analytical data. From 
spectroscopic data of compounds 3, the formation of the new pyrimidine ring is clearly observed: 
in the 1H-NMR spectra the signals for NH are absent and instead the proton or methyl attached to 
C(7) appears at 7.40-8.12 ppm or around 2.0 ppm respectively; in the 13C-NMR the C(7) appears 
at 152-164 ppm.  
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In the hope of improving the reaction efficiency, equimolar amounts of 6-amino-5-
(benzylaminomethyl)pyrimidine 2b, ethyl orthoformate and acetic acid were tried; but in this 
case in addition to the cyclization reaction we found loss of the methoxy group at C(2), clearly 
indicated in the 1H-NMR in which the NH of the lactam moiety was found (broad singlet at 
10.90 ppm) for 3j (Scheme 2). Something similar has been reported in other acid reactions in the 
presence of a nucleophile such as ethanol, which is a byproduct of the cyclocondensation 
step.26,29 
 
 
 
Scheme 2. Acetic acid in equimolar amount leads to demethylation and cyclization in the 
reaction of diaminopyrimidine 2b with ethyl orthoformate. 
 
All the pyrimidopyrimidines 3 were fully characterized, the most characteristic NMR feature 
being the afore-mentioned disappearance of the NH signals of 2 and the appearance of a new 
signal for C(7)-H in the case of 3a,c,d,f,h or -CH3 for 3b,e,g,i depending on whether ethyl 
orthoformate or methyl orthoacetate were used.  
X-Ray diffraction analysis was carried out on the pyrimido[4,5-d]pyrimidine 3a, and its 
structure was unambiguously confirmed. The most relevant feature observed in its supra-
molecular structure is the π – π stacking interactions between phenyls which is reinforced by 
weak π – π interactions between pyrimidine rings. 
 
 
 
Figure 3. ORTEP drawing of the structure 3a with 50% probability ellipsoids. 
 
In order to extend the variety of hydropyrimido[4,5-d]pyrimidines available, the tetrahydro 
derivatives were prepared from the intermediates 2 and carbonyl compounds such as acetone and 
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benzaldehyde in a similar fashion to those reported for the preparation of tetrahydroquin-
azolines.30 Mild reaction conditions were used: EtOH as solvent, a temperature of 50 ºC, and 
p-toluenesulfonic acid as catalyst, which is needed because of the low nucleophilicity of the 6-
amino group in 2 (Scheme 3 and Table 3).31  
 
 
 
Scheme 3. Synthesis of 5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4(3H)-ones 4. 
 
Table 3. Data for products 4a-g 
Entry X R1 R2 R3 
Compounds 3 
Yield (%) Mp ºC 
4a O CH2C6H5 CH3 CH3 70 222 
4b S CH2C6H5 CH3 CH3 74 220 
4c O CH2C6H5 H C6H5 72 169 
4d S CH2C6H5 H C6H5 55 156 
  4e a O C6H11 H H 40 261 
4f S C6H11 H C6H5 67 126 
4g S CH(CH3)C6H5 H C6H5   38-72 b 115 
a Compound 4e was isolated from the reaction of 2c with acetone.b See Table 4. 
 
The tetrahydropyrimidopyrimidines 4 were obtained in moderate to good yields and also 
fully characterized by spectroscopic and analytical data. From the spectroscopic data of 
compounds 4, the formation of the new tetrahydropyrimidine ring is clearly observed, for 
example in 1H-NMR spectra; as in the case of compounds 3, the signals for NH largely 
disappear, there remaining just the N(8)-H, and substituents attached to C(7) are clearly 
observed, with the new C(7) appearing in the 13C-NMR at 59-71 ppm.  
The reaction between 2c and acetone afforded an unexpected product, which was 
characterized as 4e. Its 1H-NMR spectrum shows a signal at 4.78 ppm corresponding to the 
methylene for C(7), which is coupled with the N(8)-H, but not those corresponding to the methyl 
groups expected from acetone. So the acetone is not involved in the reaction in this case, as was 
also confirmed by mass spectrometry. To prove this possibility 2c was reacted in ethanol with 
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PTSA in the absence of acetone. Under these conditions compound 4e, together with the initial 
pyrimidine precursor VI and cyclohexylamine were obtained. Therefore, compound 2c is acting 
in this reaction both as a diamine and a formaldehyde-releasing agent, to render 4e, as shown in 
Scheme 4. This behavior can be explained by of the higher basicity of the dialkylamino residue 
in molecule 2c, compared to the other diamine derivatives 2, that in acid media leads to its partial 
hydrolysis that releases formaldehyde (like in acetals) which is then trapped by another molecule 
of 2c, forming compound 4e. 
 
 
 
Scheme 4.  Compound 2c: decomposition in acid medium. 
 
From the mass spectrometry analysis for the dihydro (3) and tetrahydro (4) pyrimido[4,5-d]-
pyrimidine derivatives, similar fragmentation patterns were observed, characterized by 
progressive loss of pendant substituents and ring opening.  
A single crystal X-ray diffraction on the tetrahydropyrimido[4,5-d]pyrimidine derivative 4c 
was carried out (Figure 4), showing the predicted structure. Some considerations about the 
structure observed can be made: the puckering analysis shows a conformation of the saturated 6-
membered ring close to the twist-boat, with substituents at N(6) and C(7) in a axial disposition to 
minimize the steric interaction between them. 
 
Figure 4. ORTEP drawing of the structure 4c with 50% probability ellipsoids. 
 
When benzaldehyde is used as reagent, a stereogenic center is generated at C(7) (see Figure 
5). In the first instance we observed that in order to induce stereoselectivity in this reaction, the 
presence of a chiral residue in the starting material was needed, and therefore the enantiomeric 
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compounds 2g/2g’ were prepared by reductive amination of 1b with (R)- and (S)-
methylbenzylamine. The stereoselectivity of the reaction of 2g/2g’ with benzaldehyde was 
studied under several conditions. The conclusions of the chirality study are: slight importance of 
solvent (better results in acetonitrile than in ethanol), the necessity for a chiral auxiliary 
introduced in the molecule (R1) (2g/2g’) and also a chiral acid catalyst (camphorsulfonic acid). 
Without chiral acid catalyst the d.e. of the reaction was 4% in EtOH and 33% in acetonitrile, 
while it reaches 88% upon the addition of camphorsulfonic acid (Table 4). When the substituent 
is the isomer S and the acid is S too, the preferred configuration generated is S. Likewise, when 
starting material and catalyst are R, C(7) is also R, and in both cases the diastereomeric excess 
obtained is around 88% (see Table 4). 
 
 
 
Figure 5. Set of diasteromeric structures formed by reaction of 2g/2g′  with benzaldehyde. 
 
Table 4. Results of the stereochemical analysis of the chiral diaminopyrimidines 2g/2g′ 
Major 
isomer 
Starting chiral 
diamine (2) Conditions d.e [(D)] 
Yield 
(%) 
4g1 2g [1′R (+)] EtOH, refl. / PTSA·H2O (10%) 4%  [+16.6º] 38 
4g1 2g [1′R (+)] CH3CN, 50 ºC / PTSA·H2O (10%) 33 % 44 
4g1 2g [1′R (+)] EtOH, 50 ºC / CSA (+) (10%) 86 % 72 
4g1 2g [1′R (+)] CH3CN, 50 ºC / CSA (+) (10%) 88 %  [+84.4º] 66 
4g1 2g [1′R (+)] CH3CN, 50 ºC / CSA (-) (10%) 78 % 72 
4g4 2g′ [1′S (-)] EtOH, 50 ºC / PTSA·H2O (10%) 58 % 72 
4g4 2g′ [1′S (-)] CH3CN, 50 ºC / CSA (+) (10%) 50 % 56 
4g4 2g′ [1′S (-)] CH3CN, 50 ºC / CSA (-) (10%) 82 % [-77.2º] 68 
 
Analysis by NMR was essential to determine the stereochemistry in the 4g diasteromers and 
to calculate the diasteromeric excess for the reactions. NOESY experiments permitted 
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assignment of 4g1 as the major diastereoisomer (see figures 1S and 2S in supporting 
information). The NOESY (figure 1S) shows the correlation between C(7)-H with 1′-H for 4g1, 
but in the case of 4g2 are observed between C(7)-H with 1′-CH3 and N(8)-H with 1′-H, which 
agrees with their optimized conformations. 
 
Theoretical calculations 
To support the experimental results, theoretical calculations have been done on compound 4g1-4. 
An exhaustive conformational study has been carried out using the Multidimensional 
Conformational Analysis (MDCA).32 A combination of semiempirical (PM6) and DFT 
(B3LYP/6-31G(d)) computations were employed in order to obtain the energetically preferred 
conformations. A detailed explanation about the conformational search is given in the 
experimental section. From the low-energy conformations obtained for both diasteromers R/R 
and R/S we calculated the shielding tensors using the GIAO approach33,34 from the program 
Gaussian 03.35 Our study also includes the calculation of 13C-NMR chemical shift for the 
diasteroisomers (R/R; R/S; S/R and S/S) by using the gauge independent atomic orbital (GIAO) 
approximation. 
Observing the curves obtained in figure 6, it is evident that the correlation obtained for the 
R/R enantiomer is excellent indicating that such assignment for 4a-g is correct. Figures 6a and 6b 
give the correlations obtained for the experimentally obtained chemical shifts versus calculated 
chemical shifts obtained for R/R and R/S, respectively. 
 
a)                 b) 
       
 
Figure 6. Chemical shifts correlations: (a) assigned to R/R vs calculated for R/R, and (b) 
assigned to R/R vs calculated for R/S 
 
It is pertinent to remark that the theoretical calculations reported here are in agreement with 
the experimental results obtained from X-ray measurements. Figure 3S (supporting information) 
gives in a comparative fashion the conformations obtained from X-ray and from theoretical 
R/R exp 
R/R Cal 
R/R exp 
R/S Cal 
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calculations. The very similar spatial ordering obtained for both forms can be appreciated very 
well in this figure. 
 
Antimicrobial activity 
It should be noted that the synthesized compounds have a certain structural similarity with 
compounds IV and V shown in Figure 1 which have been reported as antibacterial agents Thus, 
we decide to test these compounds against different pathogenic fungi and bacteria. Minimum 
Inhibitory Concentration (MIC) of each compound was determined by using broth microdilution 
techniques according to the guidelines of the National Committee for Clinical Laboratory 
Standards for yeasts (M27-A3) and for filamentous fungi (M 38-A2).36 More details about these 
bioassays might be obtained from previous works.37-38 
Most of the compounds described herein were evaluated against Candida albicans, C. 
neoformans, Staphylococcus aureus methicillin-sensitive ATCC 29213, Staphylococcus aureus 
methicillin-resistant ATCC 43300, Escherichia coli ATCC 25922, LM1-Escherichia coli LM2,,  
Pseudomonas aeruginosa ATCC 27853, PI-Yersinia enterocolítica, MI-Salmonella enteritidis 
and Salmonella sp (LM). Unfortunately, none of the test compounds displayed antifungal nor 
antibacterial activity at the highest concentration tested (250 μg/mL). Other bioassays are in 
progress and will be the subject of another report in the near future. 
 
 
Conclusions 
 
We have developed the synthesis of a new series of 5,6-dihydro- and 5,6,7,8-
tetrahydropyrimido[4,5-d]pyrimidin-4(3H)-ones starting from the corresponding 4-amino-
pyrimidines, via formation of 4-amino-(5-aminomethyl)pyrimidines as intermediates. The 
cyclocondensation was achieved using orthoesters under MW irradiation and solvent-free 
conditions. This latter reaction was optimized by acid catalyst to get the desired products in just 
1 minute in good yields. This methodology is straightforward and the isolation of desired 
products is simple. These compounds have an attractive skeleton from a biological point of view, 
and they are being tested with the aim to find potential pharmacological applications. 
 
 
Experimental Section 
 
General. Melting points were determined on a Barstead Electrothermal 9100 melting point 
apparatus. IR spectra were recorded in KBr disks on a Bruker TENSOR 27 spectrophotometer at 
“Centro de Instrumentación Científico-Técnica (CICT) at Universidad de Jaén”. 1H and 13C 
NMR spectra were recorded on a Bruker Avance 400 spectrophotometer (CICT) operating at 400 
MHz and 100 MHz respectively, using CDCl3 and DMSO-d6 as solvents and tetramethylsilane as 
internal standard; the carbon type described p (primary), s (secondary), t (tertiary) and q 
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(quaternary) at 13C-NMR was done using DEPT-135 and 2D-NMR experiments. Mass spectra 
were run on a Shimadzu-GCMS 2010-DI-2010 spectrometer (equipped with a direct inlet probe) 
operating at 70 eV. High resolution mass spectra were run on a Waters Micromass AutoSpec-
Ultima spectrometer equipped with a direct inlet probe operating at 70 eV. Silica gel aluminum 
plates (Merck 60 F254) were used for analytical TLC. The microwave-assisted reactions were 
carried out in a 10 ml glass sealed vial for focused mono-mode microwaves oven (Discover, by 
CEM Corp.) working in standard mode by controlling the target temperature. The starting 
amines and orthoesters were purchased from Aldrich, Fluka and Acros (analytical reagent 
grades) and were used without further purification. 
 
Reductive amination of 6-aminopyrimidine-5-carbaldehydes (1): 6-amino-5-[(substituted-
amino)methyl]pyrimidin-4(3H)-ones (2). General procedure. The 6-aminopyrimidine-5-
carbaldehyde (1) (1 mmol) was suspended in anhydrous THF under argon. The requisite primary 
amine (2 mmol) and then sodium triacetoxyborohydride (2 mmol) were added and stirred was 
continued overnight at room temperature. The solvent was removed under reduced pressure and 
water (20 mL) was added. The solution was neutralized with aqueous sodium hydroxide (2 M). 
The desired colorless product (2) was precipitated, filtered off, and washed with water. 
 
6-Amino-2-methoxy-3-methyl-5-[(phenylamino)methyl]pyrimidin-4(3H)-one (2a) from 1a 
and aniline, yield 98 %. Mp 250-3 ºC. IR (KBr): 3358 (b,m); 3182 (m); 2953 (w); 1644 (b,s); 
1541 (b,s); 1485 (m); 1452 (m); 1411 (m); 1216 (m). 1H-NMR (DMSO-d6) δ (ppm): 3.19 (s, 
3H); 3.87 (s, 3H); 3.94 (d, 5.4 Hz, 2H); 5.47 (t, 5.4 Hz, 1H); 6.35 (s, 2H); 6.46 (t, 7.2 Hz, 1H); 
6.61 (d, 7.2 Hz, 2H); 7.00 (t, 7.2 Hz, 2H). 13C-NMR (DMSO-d6) δ (ppm): 27.0 p; 37.1 s; 55.0 p; 
87.9 q; 112.3 t; 115.3 t; 128.6 t; 148.7 q; 155.1 q; 159.4 q; 162.0 q. MS (70 eV) m/z (%): 260 
(M+, 10); 257 (23); 168 (100); 111 (10); 93 (3); 77 (5). HRMS (EI, 70 eV): calc for C13H14N4O2 
260.1273; found 260.1270. 
6-Amino-5-[(benzylamino)methyl]-2-methoxy-3-methylpyrimidin-4(3H)-one (2b) from 1a 
and benzylamine, yield 82 %. Mp 125-7 ºC. IR (KBr): 3360 (m); 3311 (m); 3200 (b,m); 2952 
(w); 2853 (w); 1623 (b,s); 1540 (b,s); 1487 (m); 1221 (m). 1H-NMR (DMSO-d6) δ (ppm): 3.16 
(s, 3H), 3.52 (s, 2H), 3.60 (s, 2H); 3.88 (s, 3H); 6.47 (s, 2H); 7.17 – 7.24 (m, 2H); 7.25 – 7.30 
(m, 4H). 13C-NMR (DMSO-d6) δ (ppm): 26.9 p; 42.9 s; 52.0 s; 55.0 p; 88.1 q; 127.4 t; 127.9 t; 
128.0 t; 141.0 q; 155.0 q; 159.7 q; 161.9 q. MS (70 eV) m/z (%): 272 (M+, 4); 183 (100); 169 
(83); 91 (30). HRMS (IE, 70 eV): calc for C14H16N4O2 272.1273; found 272.1271.  
6-Amino-5-[(cyclohexylamino)methyl]-2-methoxy-3-methylpyrimidin-4(3H)-one (2c) from 
1a and cyclohexylamine, yield 80 %. Mp 210-2 ºC. IR (KBr): 3371 (s); 3296 (m); 3182 (b,m); 
2920 (m); 2853 (m); 1635 (b,s); 1598 (m); 1546 (b,s); 1452 (s). 1H-NMR (DMSO-d6) δ 
(ppm):0.94 – 1.02 (m, 2H); 1.08 – 1.18 (m, 3H); 1.48 – 1.52 (m, 1H); 1.61 – 1.63 (m, 2H); 1.79 – 
1.82 (m, 2H); 2.26 – 2.31 (m, 1H); 3.15 (s, 3H); 3.50 (s, 2H); 3.87 (s, 3H); 6.49 (s, 2H). 13C-
NMR (DMSO-d6) δ (ppm): 24.4 s; 25.9 s; 26.9 p; 32.8 s; 40.3 s; 54.8 t; 54.9 p; 88.5 q; 154.9 q; 
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159.7 q; 161.7 q. MS (70 eV) m/z (%): 183 (100); 168 (61); 111 (13); 98 (20); 56 (22). HRMS 
(IE, 70 eV): calc for C13H20N4O2 264.1586; found 264.1588. 
6-Amino-3-methyl-2-(methylthio)-5-[(phenylamino)methyl]pyrimidin-4(3H)-one (2d) from 
1b and aniline, yield 92 %. Mp 175-7 ºC. IR (KBr): 3486 (m); 3386 (s); 3298 (m); 2922 (w); 
2844 (w); 1600 (b,s); 1524 (b,s); 1317 (m); 1093 (m). 1H-NMR (DMSO-d6) δ (ppm): 2.48 (s, 
3H); 3.31 (s, 3H); 3.96 (d, 5.6 Hz, 2H); 5.51 (t, 5.6 Hz, 1H); 6.40 (sa, 2H); 6.47 (pt, 6.4 Hz, 1H); 
6.61 (pd, 6.4 Hz, 2H); 7.00 (pt, 7.2 Hz, 2H). 13C-NMR (DMSO-d6) δ (ppm): 14.1 p; 29.5 p; 37.0 
s; 89.8 q; 112.4 t; 115.4 t; 128.7 t; 148.6 q; 158.7 q; 159.8; 161.5 q. MS (70 eV) m/z (%): 276 
(M+, 10); 184 (100); 138 (5); 93 (15). HRMS: calc for C13H16N4OS 276.1045; found 276.1047. 
6-Amino-5-[(benzylamino)methyl]-3-methyl-2-(methylthio)pyrimidin-4(3H)-one (2e) from 
1b and benzylamine (0.22 ml) (78 %). M. p. 118-21 ºC. IR (KBr): 3381 (m); 3284 (m); 2922 
(w); 2859 (w); 1605 (b,s); 1513 (s); 1459 (m); 1411 (m); 1089 (m). 1H-NMR (DMSO-d6) δ 
(ppm): 2.45 (s, 3H); 3.24 (s, 3H); 3.50 (s, 2H); 3.56 (s, 2H); 6.49 (sa, 2H); 7.10 – 7.20 (m, 1H); 
7.20 – 7.30 (m, 4H). 13C-NMR (DMSO-d6) δ (ppm): 14.1 p; 29.4 p; 42.8 s; 52.1 s; 90.1 q; 126.5 
t; 127.9 t; 128.1 t; 140.9 q; 159.2 q; 159.6 q; 161.5 q. MS (70 eV) m/z (%): 288 (8); 199 (100); 
185 (68); 138 (15); 91 (17). HRMS: calc for C14H18N4OS 288.1045; found 288.1039. 
6-Amino-5-[(cyclohexylamino)methyl]-3-methyl-2-(methylthio)pyrimidin-4(3H)-one (2f) 
from 1b and cyclohexylamine (0.2 ml) (90 %). IR (KBr): 3380 (s); 3184 (b,m); 2918 (m); 2850 
(m); 1607 (b,s); 1576 (m); 1521 (s); 1410 (m); 1095 (m). Mp 140-2 ºC. 1H-NMR (DMSO-d6) δ 
(ppm): 0.96 – 1.03 (m, 2H); 1.09 – 1.22 (m, 3H); 1.50 – 1.54 (m, 3H); 1.80 – 1.83 (m, 2H); 2.26 
– 2.31 (m, 1H); 2.50 (s, 3H); 3.28 (s, 3H); 3.53 (s, 2H); 6.53 (sa, 2H). 13C-NMR (DMSO-d6) δ 
(ppm): 14.0 p; 24.4 s; 25.9 s; 29.3 p; 32.9 s; 40.2 s; 54.8 t; 90.6 q; 159.1 q; 159.2 q; 161.2 q. MS 
(70 eV) m/z (%):199 (100); 184 (64); 138 (11); 98 (28); 56 (21). HRMS: calc for C13H22N4OS 
282.1514; found 282.1507. 
(R)-6-Amino-3-methyl-2-methylthio-5-[[(1-phenylethyl)amino]methyl]pyrimidin-4(3H)-one 
(2g) from 1b and D(+)-α-methylbenzylamine. The product was extracted with DCM (3 × 20 
mL). The organic extracts were dried over anhydrous Na2SO4, and solvents removed under 
reduced pressure to afford an oily residue. The product was purified by flash chromatography 
(eluent DCM/MeOH 9:1;column diam. 2cm) to give a colorless oil (86%). [α]D + 75.8 (DCM; 25 
ºC; 0.01g/L). IR (KBr): 3442 (m, b); 2959 (w); 2924 (m); 2852 (w); 1630 (s, b); 1516 (s, b); 
1452 (m); 1412 (m); 1095 (m, b). 1H-NMR (DMSO-d6) δ (ppm): 1.41 (d, 6.6 Hz, 3H); 2.49 (s, 
3H); 3.41 (s, 3H); 3.47 (d, 13.2 Hz, 1H), 3.74 (d, 13.2 Hz, 1H); 3.84 (q, 6.6 Hz, 1H); 5.45 (sa, 
2H); 7.24 –7.27 (m, 1H); 7.31 – 7.37 (m, 4H). 13C-NMR (DMSO-d6) δ (ppm): 14.6 p: 23.5 p; 
30.0 p; 42.1 s; 58.2 t; 91.8 q; 126.7 t;127.3 t; 128.6 t; 144.6 q; 159.6 q; 160.8 q; 162.5 q. MS (70 
eV) m/z (%):211 (47); 199 (100); 184 (48); 138 (8); 120 (74); 105 (25); 88 (15). HRMS: calc for 
C15H20N4OS: 316.1358; found 316.1356. 
(S)-6-Amino-3-methyl-2-methylthio-5-[[(1-phenylethyl)amino]methyl]pyrimidin-4(3H)-one 
(2g′) from 1b (1 mmol) and L(-)-α-methylbenzylamine. The workup as for 2g gave a colorless 
oil (81%). [α]D -74.4 (DCM; 25 ºC; 0.01g/L). NMR and IR are the same as for 2g. MS (70 eV) 
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m/z (%): 211 (4547); 199 (100); 184 (5348); 138 (8); 120 (7374); 105 (25); 88 (1315).. HRMS: 
calc for C15H20N4OS: 316.1358; found 316.1355. 
Synthesis of pyrimido[4,5-d]pyrimidines (3) by cyclocondensation of 2 with orthoesters: 
general procedure. A mixture of 6-amino-5-aminomethylpyrimidine (2) (1 mmol), the 
orthoester (0.5 ml) and acetic acid (one drop) was placed into a sealed MW glass tube and 
irradiated in the microwave oven for 1 minute (150 ºC, max. power 200W). After cooling, 
hexane was added and the solid that separated was filtered off, washed with cold diethyl ether, 
and recrystallized from ethanol. 
6-Benzyl-2-methoxy-3-methyl-5,6-dihydropyrimido[4,5-d]pyrimidin-4(3H)-one (3a) from 2b 
and triethyl orthoformate: colorless solid (65 %). Mp 175-82 ºC. IR (KBr): 2955 (b,w); 1705 
(m); 1654 (b,s); 1556 (b,m); 1496 (m); 1455 (m); 1436 (m); 1212 (m); 1156 (m). 1H-NMR 
(CDCl3) δ (ppm): 3.33 (s, 3H); 4.03 (s, 3H); 4,23 (s, 2H); 4.33 (s, 2H); 7.28 (pd, 7.0 Hz, 2H); 
7.33 – 7.41 (m, 3H); 7.40 (s, 1H). 13C-NMR (CDCl3) δ (ppm): 27.6 p; 43.3 s; 55.8 p; 57.4 s; 91.5 
q; 127.9 t; 128.5 t; 129.0 t; 133. 5 q; 155.9 t; 156.5 q; 157.9 q; 161.6 q. MS (70 eV) m/z (%): 284 
(M+, 5); 193 (20); 182 (13); 168 (20); 133 (17); 106 (35); 91 (100); 75 (31); 65 (37). HRMS: calc 
for C15H16N4O2 284.1273; found 284.1271. 
Crystal data for 3a were deposited at CCDC with reference 809643: Chemical formula 
C15H16N4O2, Mr 284.32, Orthorombic, Pbca, 120 K, cell dimensions a, b, c (Å) 17.948 (5), 
7.8393 (15), 18.8278 (13); , ,  (°) 90, 90, 90, V (Å3) 2649.1 (9), Z= 8, F(000)=1200, Dx (Mg 
m-3) = 1.426, Mo K (mm-1)=0.10, Crystal size (mm)= 0.3 × 0.24 × 0.22. Data collection: 
Diffractometer KappaCCD diffractometer, Monochromator graphite, CCD rotation images, thick 
slices  & scans, absorption correction SADABS 2.10, Tmin, Tmax 0.971, 0.979. No. of measured, 
independent and observed [I > 2(I)] reflections 23485, 3043, 2071, Rint=0.064,  values (°): max 
= 27.5, min = 3.1;  Range h = -2323, k = -108, l = -2224, Refinement on F2:R[F2 > 
2(F2)]=0.048, wR(F2)=0.128, S=1.09. No. of reflections 3043, No. of parameters 192, No. of 
restraints 0. Weighting scheme:  w = 1/[2(Fo2) + (0.0505P)2 + 1.7324P]  where P = (Fo2 + 
2Fc2)/3. (/)max=0.001, max, min (e Å-3) 0.31, -0.34. 
6-Benzyl-2-methoxy-3,7-dimethyl-5,6-dihydropyrimido[4,5-d]pyrimidin-4(3H)-one (3b) 
from 2b and trimethyl orthoacetate: yellow solid (49 %). Mp 142-3 ºC. IR (KBr): 3006 (w); 2955 
(b,w); 2861 (b,w); 2811 (w); 1736 (w); 1666 (s); 1599 (m); 1558 (s); 1533 (s); 1471 (b,s); 1430 
(m); 1412 (m). 1H-NMR (CDCl3) δ (ppm): 2.29 (s, 3H); 3.34 (s, 3H); 4.05 (s, 3H); 4.34 (s, 2H); 
4.51 (s, 2H); 7.24-7.39 (m, 5H). 13C-NMR (CDCl3) δ (ppm): 22.5 p; 27.6 p; 46.2 s; 54.8 s; 55.8 
p; 91.5 q; 126.6 t; 128.1 t; 129.1 t; 134.1 q; 156.6 q; 158.0 q; 161.4 q; 164.2 q. MS (70 eV) m/z 
(%): 298 (M+, 2); 207 (27); 91 (100). HRMS: calc for C16H18N4O2 298.1430; found 298.1429. 
6-Cyclohexyl-2-methoxy-3-methyl-5,6-dihydropyrimido[4,5-d]pyrimidin-4(3H)-one (3c) 
from 2c and triethyl orthoformate: colorless solid (80 %). Mp 226-8 ºC. IR (KBr): 3177 (m); 
2932 (m); 2856 (w); 1635 (b,s); 1548 (b,s); 1487 (m); 1455 (m); 1410 (m); 1377 (m). 1H-NMR 
(CDCl3) δ (ppm): 1.15-1.24 (m, 1H); 1.32-1.41 (m, 2H); 1.57-1.66 (m, 2H); 1.72 (pd, 13.8 Hz, 
1H); 1.93 (pd, 10.7 Hz, 4H); 3.31-3.38 (m, 1H); 3.38 (s, 3H); 4.05 (s, 3H); 4.44 (s, 2H); 8.12 (s, 
1H). 13C-NMR (CDCl3) δ (ppm): 24.8 s; 25.1 s; 27.9 p; 30.1 s; 41.4 s; 56.4 p; 64.4 t; 90.3 q; 
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153.0 q; 154.1 t; 157.2 q; 161.1 q. MS (70 eV) m/z (%): 276 (M+, 55); 275 (71); 261 (22); 193 
(100); 179 (24); 136 (17); 83 (4). HRMS: calc for C14H20N4O2 276.1586; found 276.1589. 
3-Methyl-2-(methylthio)-6-phenyl-5,6-dihydropyrimido[4,5-d]pyrimidin-4(3H)-one (3d) 
from 2d and triethyl orthoformate. Colorless solid (75 %). Mp 173-5 ºC. IR (KBr): 3063 (w); 
2924 (w); 2854 (w); 1655 (b,s); 1594 (m); 1547 (m); 1516 (s); 1437 (m); 1405 (b,m); 1225 (m). 
1H-NMR (CDCl3) δ (ppm): 2.64 (s, 3H); 3.51 (s, 3H); 4.85 (s, 2H); 7.24-7.31 (m, 3H); 7.45 (pt, 
7.4 Hz, 2H); 7.79 (s, 1H). 13C-NMR (CDCl3) δ (ppm): 15.0 p; 30.1 p; 44.2 s; 94.4 q; 119.2 t; 
126.4 t; 129.8 t; 142.0 q; 153.2 t; 156.5 q; 160.9 q; 162.6 q. MS (70 eV) m/z (%): 286/288 
(M/M+2, 66/13); 271 (47); 198 (24); 77 (100). HRMS: calc for C14H14N4OS 286.0888; found 
286.0891. 
3,7-Dimethyl-2-(methylthio)-6-phenyl-5,6-dihydropyrimido[4,5-d]pyrimidin-4(3H)-one (3e) 
from 2d and trimethyl orthoacetate: yellow solid (60 %). Mp 145-8 ºC. IR (KBr): 3039 (w); 2928 
(w); 1724 (m); 1645 (b,s); 1513 (b,s); 1477 (m); 1448 (b,m); 1410 (m); 1342 (m). 1H-NMR 
(DMSO-d6) δ (ppm): 1.81 (s, 3H); 2.50 (s, 3H); 3.34 (s, 3H); 4.54 (s, 2H); 7.35-7.41 (m, 1H); 
7.44-7.51 (m, 4H). 13C-NMR (DMSO-d6) δ (ppm): 14.4 p; 23.0 p; 29.6 p; 48.8 s; 93.2 q; 126.3 t; 
128.0 t; 129.9 t; 143.3 q; 157.1 q; 159.5 q; 161.0 q; 162.8 q. MS (70 eV) m/z (%): 300 (M+, 62); 
299 (100); 285 (42); 77 (27). HRMS: calc for C15H16N4OS 300.1045; found 300.1044. 
6-Benzyl-3-methyl-2-(methylthio)-5,6-dihydropyrimido[4,5-d]pyrimidin-4(3H)-one (3f) 
from 2e and triethyl orthoformate: colorless solid (70 %). Mp 126 ºC. IR (KBr): 2996 (w); 2931 
(w); 1701 (s); 1661 (b,s); 1560 (s); 1519 (s); 1461 (m); 1428 (s); 1367 (b,s); 1284 (b,m). 1H-
NMR (CDCl3) δppm: 2.61 (s, 3H); 3.43 (s, 3H); 4.25 (s, 2H); 4.33 (s, 2H); 7.27-7.38 (m, 5H); 
7.41 (s, 1H). 13C-NMR (CDCl3) δ (ppm): 15.0 p; 29.9 p; 43.1 s; 57.5 s; 93.5 q; 127.9 t; 128.6 t; 
129.1 t; 133.4 q; 156.0 t; 157.4 q; 161.1 q; 162.1 q. MS (70 eV) m/z (%): 300 (M+, 4); 209 (33); 
91 (100). HR MS: calc for C15H16N4OS 300.1045; found 300.1042. 
6-Benzyl-3,7-dimethyl-2-(methylthio)-5,6-dihydropyrimido[4,5-d]pyrimidin-4(3H)-one (3g) 
from 2e and trimethyl orthoacetate: yellow solid (67 %). Mp 114-16 ºC. 1H-NMR (CDCl3) δ 
(ppm): 2.30 (s, 3H); 2.63 (s, 3H); 3.44 (s, 3H); 4.36 (s, 2H); 4.51 (s, 2H); 7.24-7.39 (m, 5H). 13C-
NMR (CDCl3) δ (ppm): 14.9 p; 22.6 p; 29.6 p; 46.0 s; 54.8 s; 93.5 c, 126.6 t; 128.1 t; 129.1 t; 
134.0 q; 157.6 q; 160.8 q; 162.0 q; 164.3 q. IR (KBr): 2999 (w); 2927 (w); 2841 (w); 1720 (w); 
1650 (b,s); 1519 (b,s); 1484 (m); 1453 (m); 1408 (m). MS (70 eV) m/z (%): 314/316 (M/M+2, 
4/1); 223 (37); 91 (100). HR MS: calc for C16H18N4OS 314.1197; found 314.1201. 
6-Cyclohexyl-3-methyl-2-(methylthio)-5,6-dihydropyrimido[4,5-d]pyrimidin-4(3H)-one (3h) 
from 2f and triethyl orthoformate: colorless solid (69 %). Mp 187-91 ºC. IR (KBr): 2934 (w); 
2856 (m); 1709 (m); 1650 (b,s); 1591 (m); 1520 (b,s); 1460 (m); 1412 (m). 1H-NMR (CDCl3) δ 
(ppm): 1.15 (tq, 3.7 y 13.0 Hz, 1H); 1.35 (qt, 3.7, 13.0 Hz, 2H); 1.60 (qd, 3.5 Hz y 12.0 Hz, 2H); 
1.70 (pd, 13.7 Hz, 1H); 1.89 (pt, 13.2 Hz, 4H); 2.60 (s, 3H); 3.20 (tt, 3.3 Hz y 12.0 Hz, 1H); 3.47 
(s, 3H); 4.43 (s, 2H); 7.65 (s, 1H). 13C-NMR (CDCl3) δ (ppm): 15.0 p; 24.9 s; 25.2 s; 30.0 p; 30.1 
s; 63.4 t; 92.6 q; 154.8 t; 155.6 q; 160.8 q; 162.8 q. MS (70 eV) m/z (%): 292/294 (M/M+2, 
72/5); 277 (29); 209 (100); 195 (22); 83 (4). HRMS: calc for C14H20N4OS 292.1358; found 
292.1351. 
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6-Cyclohexyl-3,7-dimethyl-2-(methylthio)-5,6-dihydropyrimido[4,5-d]pyrimidin-4(3H)-one 
(3i) from 2f and trimethyl orthoacetate: yellow solid (53 %). Mp 235-40 ºC. IR (KBr): 3180 
(b,w); 3124 (b,w); 2935 (b,w); 2886 (w); 1691 (m); 1641 (b,s); 1591 (s); 1523 (s); 1485 (m); 
1405 (m). 1H-NMR (CDCl3) δ (ppm): 1.12 (tq, 3.7 Hz, 13.2 Hz, 1H); 1.27-1.40 (m, 2H); 1.69-
1.72 (m, 4H); 1.90 (pd, 13.8 Hz, 2H); 2.24 (s, 3H); 2.61 (s, 3H); 3.47 (s, 3H); 3.59-3.68 (m, 1H); 
4.35 (s, 2H). 13C-NMR (CDCl3) δ (ppm): 15.0 p; 22.8 p; 25.1 s; 25.6 s; 29.1 s; 29.9 p; 39.4 s; 
59.0 t; 92.9 q; 158.0 q; 160.9 q; 161.8 q; 164.0 q. MS (70 eV) m/z (%): 305/307 (M/M+2, 26/7); 
223 (100); 209 (17); 177 (10); 83 (20). HRMS: calc for C15H22N4OS 306.1514; found 306.1509. 
6-Benzyl-3-methyl-5,6-dihydropyrimido[4,5-d]pyrimidin-2,4(1H,3H)-dione (3j) from 2b, 
triethyl orthoformate and 0.06 ml of acetic acid for 5 minutes: yellow solid (25%). Mp 239-41 
ºC. IR (KBr): 3097 (b,w); 2883 (b,w); 2782 (b,w); 1709 (m); 1662 (s); 1625 (s); 1581 (m); 1453 
(b,m); 1436 (m). 1H-NMR (DMSO-d6) δ (ppm): 3.03 (s, 3H); 3.94 (s, 3H); 4.48 (s, 2H); 7.35-
7.43 (m, 5H); 7.67 (s, 1H); 10.90 (ws, 1H). 13C-NMR (DMSO-d6) δ (ppm): 26.0 p; 41.5 s; 55.8 s; 
82.0 q; 128.0 t; 128.1 t; 128.6 t; 134.3 q; 150.2 q; 150.7 q; 156.6 t; 161.5 q. MS (70 eV) m/z (%): 
270 (M+, 4); 179 (29); 91 (100); 65 (25). HRMS: calc for C14H14N4O2 270.1117; found 
270.1116. 
Synthesis of pyrimido[4,5-d]pyrimidines (4) by reaction with carbonyl compounds: general 
procedure. The 6-amino-5-(aminomethyl)pyrimidine (2) (1 mmol) in a solvent (3ml), the 
carbonyl compound (1 mmol) and catalytic acid (0.05 mmol) were stirred and heated to 50 ºC. 
for the  indicated time. The solution was then cooled to room temperature, The product was 
collected by filtration, washed with cold diethyl ether and recrystallized from EtOH. 
6-Benzyl-3,7,7-trimethyl-2-methoxy-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4(3H)-one 
(4a) from 2b in EtOH, acetone and p-TsOH·H2O. Reaction time: 20h. Colorless solid (70%).    
Mp 222 ºC. IR (KBr): 3285 (s); 2962 (m); 2801 (w); 2769 (w); 1639 (s); 1616 (s); 1598 (s); 1531 
(s); 1223 (s). 1H-NMR (CDCl3). δ (ppm): 1.45 (s, 6H); 3.32 (s, 3H); 3.60 (s, 2H); 3.61 (s, 2H); 
3.93 (s, 3H); 4.83 (s, 1H); 7.20 (pt, 7.0 Hz, 1H); 7.25-7.35 (m, 4H). 13C-NMR (CDCl3). δ (ppm): 
27.00 p; 27.14 p; 43.38 s; 53.19 s; 55.10 p; 69.45 q; 85.70 q; 126.74 t; 128.26 t; 128.39 t; 140.06 
q; 154.64 q; 155.86 q; 161.48 q. MS (70eV) m/z (%): 314 (M+, 9); 299 (46); 223 (16); 207 (35); 
194 (18); 168 (95); 146 (45); 91 (100). HRMS: calc for C17H22N4O2 314.1743; found 314.1730. 
6-Benzyl-3,7,7-trimethyl-2-(methylthio)-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4(3H)-
one (4b) from 2e in EtOH, acetone and p-TsOH·H2O. Reaction time: 22h. Colorless solid (74%). 
Mp 219-21 ºC. IR (KBr): 3293 (s); 2993 (w); 2927 (w); 2840 (w); 1628 (s); 1595 (s); 1539 (s); 
1497 (s); 1164 (m). 1H-NMR (CDCl3). δ (ppm): 1.46 (s, 6H); 2.51 (s, 3H); 3.43 (s, 3H); 3.60 (s, 
2H); 3.63 (s, 2H); 4.89 (s, 1H); 7.20 (pt, 7.0 Hz, 1H); 7.25-7.35 (m, 4H).13C-NMR (CDCl3). 
δppm: 14.66 p; 27.07 p; 29.55 p; 43.25 s; 53.20 s; 69.39 q; 87.78 q; 126.79 t; 128.29 t; 128.38 t; 
139.95 q; 154.52 q; 160.84 q. MS (70eV) m/z (%): 330 (M+, 7); 315 (49); 223 (33); 210 (17); 
184 (55); 146 (65); 91 (100). HRMS: calc for C17H22N4OS 330.1514; found 330.1511. 
6-Benzyl-2-methoxy-3-methyl-7-phenyl-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4(3H)-
one (4c) from 2b in EtOH, benzaldehyde and p-TsOH·H2O. Reaction time: 1h 30min. 10 ml of 
water is added to the reaction mixture and neutralized with NaHCO3, extracted with DCM (20ml 
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× 3) and dried with Na2SO4. The solvent is evaporated under reduced pressure. Colorless solid 
(72%). Mp 168-70 ºC. IR (KBr): 3301 (m, b); 3026 (w); 2942 (w); 2903 (w); 2850 (w); 1658 (s, 
b); 1608 (m); 1548 (s); 1519 (s, b); 1428 (m). 1H-NMR (CDCl3). δ (ppm): 3.33 (s, 3H); 3.47 (d, 
15.9Hz, 1H); 3.58 (d, 15.9Hz, 1H); 3.67 (d, 13.2Hz, 1H); 3.73 (d, 13.2Hz, 1H); 3.99 (s, 3H); 
5.07 (bs, 1H); 5.16 (bs, 1H); 7.26-7.44 (m, 10H). 13C-NMR (CDCl3). δ (ppm): 27.21 p; 43.00 s; 
55.23 p; 56.97 s; 71.24 t; 86.18 q; 126.82 t; 127.22 t; 127.98 t; 128.38 t; 128.46 t; 128.97 t; 
138.77 q; 141.04 q; 154.72 q; 155.94 q; 161.41 q. MS (70eV) m/z (%): 361 (M+-1, 50); 285 (59); 
271 (59); 257 (45); 242 (41); 168 (83); 91(100). HR MS: calc for C21H22N4O2 362.1743; found 
362.1732.  
Crystal data for 4c were deposited at CCDC with reference CCDC 945842: Chemical formula 
C21H22N4O2, Mr 362.43, Monoclinic, C2/c, 120 K, cell dimensions a, b, c (Å) 21.527 (3), 
11.1709 (8), 17.448 (4); , ,  (°) 90, 120,144 (11), 90, V (Å3) 3628,5 (10), Z= 8, F(000)=1200, 
Dx (Mg m-3) = 1.426, Mo K (mm-1)=0.10, Crystal size (mm)= 0.32 × 0.25 × 0.22. Data 
collection: Diffractometer KappaCCD diffractometer, Monochromator graphite, CCD rotation 
images, thick slices  & scans, absorption correction SADABS 2.10, Tmin, Tmax 0.9724, 0.9809. 
No. of measured, independent and observed [I > 2(I)] reflections 27121, 4163, 2179, Rint= 
0.095,  values (°): max = 27.5, min = 5.0;  Range h = -2323, k = -108, l = -2224, 
Refinement on F2:R[F2 > 2(F2)]=0.058, wR(F2)=0.167, S=1.07. No. of reflections 4163, No. of 
parameters 246, No. of restraints 0. Weighting scheme:  w = 1/[2(Fo2) + (0.0505P)2 + 1.7324P]  
where P = (Fo2 + 2Fc2)/3. (/)max< 0.001, max, min (e Å-3) 0.25, -0.31. 
6-Benzyl-3-methyl-2-(methylthio)-7-phenyl-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-
4(3H)-one (4d) from 2e in EtOH, benzaldehyde and p-TsOH·H2O. Reaction temperature: reflux. 
Reaction time: 40min. Colorless solid (55%). Mp 155-7 ºC. IR (KBr): 3261 (m, b); 3030 (w); 
2842 (w); 1654 (s); 1629 (s); 1595 (s); 1527 (s); 1508 (s); 1073 (m). 1H-NMR (CDCl3). δ (ppm): 
2.55 (s, 3H); 3.44 (s, 3H); 3.49 (d, 16.4Hz, 1H); 3.60 (d, 16.4Hz, 1H); 3.67 (d, 13.5Hz, 1H); 3.73 
(d, 13.5Hz, 1H); 5.08 (s, 1H); 5.26 (s, 1H); 7.26-7.44 (m, 10H). 13C-NMR (CDCl3). δ (ppm): 
14.72 p; 29.62 p; 42.81 s; 57.03 s; 71.08 t; 88.21 c; 126.79 t; 127.22 t; 128.00 t; 128.37 t; 128.46 
t; 128.93 t; 138.66 q; 140.98 q; 154.54 q; 160.76 q; 160.88 q. MS (70eV) m/z (%): 378 (M+, 38); 
301 (57); 287 (48); 273 (38); 256 (22); 184 (62); 91(100); 88 (34). HRMS: calc for C21H22N4OS 
378.1514; found 378.1508. 
6-Cyclohexyl-3-methyl-2-methoxy-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4(3H)-one 
(4e) from 2c in EtOH and p-TsOH·H2O. Reaction time: 15h. Colorless solid (40%). Mp 260-3 
ºC. IR (KBr): 3251 (m, b); 2927 (m); 2853 (m); 1640 (s, b); 1607 (m); 1557 (s); 1527 (s); 1462 
(m); 1415 (m). 1H-NMR (CDCl3). δ (ppm): 1.10-1.29 (m, 5H); 1.60 (pd, 11.2 Hz, 1H); 1.74-1.81 
(m, 2H); 1.97 (pd, 10.3 Hz, 2H); 2.44-2.52 (m, 1H); 3.33 (s, 3H); 3.76 (s, 2H); 3.91 (s, 3H); 4.23 
(d, 2.9Hz, 2H); 4.78 (bs, 1H). 13C-NMR (CDCl3). δ (ppm): 25.43 s; 25.94 s; 27.18 p; 30.63 s; 
43.97 s; 55.12 p; 58.39 t; 59.60 s; 87.51 q; 155.68 q; 156.24 q; 161.27 q. MS (70eV) m/z (%): 
278 (M+, 53); 277 (100); 195 (76); 180 (98); 168 (58); 72 (26); 55 (34). HRMS: calc for 
C14H22N4O2 278.1743; found 278.1738. 
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6-Cyclohexyl-3-methyl-2-(methylthio)-7-phenyl-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimi-
din-4(3H)-one (4f) From 2f in EtOH, benzaldehyde and ()camphor-10-sulfonic acid. Reaction 
time: 22h. Colorless solid (67%). Mp 189-90 ºC. 1H-NMR (CDCl3). δ (ppm): 1.11-1.50 (m, 5H); 
1.57 (bs, 1H); 1.69-1.83 (m, 2H); 1.89 (pd, 12.4 Hz, 1H); 1.98 (pd, 12.4 Hz, 1H); 2.49-2.58 (m, 
4H); 3.32 (d, 16.7Hz, 1H); 3.43 (s, 3H); 3.80 (d, 16.7Hz, 1H); 5.22 (s, 1H); 5.41 (s, 1H); 7.22-
7.40 (m, 5H). 13C-NMR (CDCl3). δ (ppm): 14.7 p; 25.4 s; 25.5 s; 26.0 s; 29.6 p; 30.5 s; 31.9 s; 
58.4 t; 69.8 t; 89.5 c; 126.8 t; 127.7 t; 128.4 t; 142.0 q;155.2 q; 160.2 q; 160.6 q. IR (KBR): 3332 
(m, b); 2930 (m); 2851 (m); 1644 (s, b); 1593 (s); 1581 (s); 1511 (s, b); 1073 (m). MS (70eV) 
m/z (%): 370 (M+, 64); 369 (42); 355 (32); 293 (83); 287 (82); 272 (100); 184 (56); 98 (30); 88 
(60). HRMS: calc for C20H26N4OS 370.1827; found 370.1823. 
3-Methyl-2-(methylthio)-7(R)-phenyl-6-[(R)-1-phenylethyl]-5,6,7,8-tetrahydropyrimido-
[4,5-d]pyrimidin-4(3H)-one (4g1) from 2g in CH3CN, benzaldehyde and (R)-camphor-10-
sulfonic acid (CSA-R). Reaction time: 18h. Colorless solid (66%). Mp 160-2 ºC. [α]D +84.4 
(DCM; 25ºC; 0.01g/l). 1H-NMR (CDCl3). δ (ppm): 1.39 (d, 6.6Hz, 3H); 2.56 (s, 3H); 3.31 (d, 
17.2Hz, 1H); 3.45 (s, 3H); 3.73 (q, 6.6Hz, 1H); 4.07 (dd, 1.9 y 17.2Hz, 1H); 4.98 (d, 3.5Hz, 1H); 
5.14 (d, 3.5Hz, 1H); 7.23-7.29 (m, 6H); 7.34-7.36 (m, 2H); 7.50-7.55 (m, 2H). 13C-NMR 
(CDCl3). δ (ppm): 14.7 p; 21.8 p; 36.9 s; 58.7 t; 69.8 t; 87.2 c; 126.5 t; 127.6 t; 128.3 t; 128.6 t; 
129.0 t; 129.7 t; 134.4 t; 142.1 q; 145.4 q; 154.9 q; 160.6 q; 160.9 q. IR (KBR): 3266 (m, b); 
3030 (w); 2975 (w); 2928 (w); 2865 (w); 1700 (m); 1638 (s); 1595 (s); 1539 (s); 1510 (s); 1554 
(m); 1413 (m). MS (70eV) m/z (%): 392 (M+, 14); 315 (15); 287 (100); 273 (22); 258 (30); 184 
(43); 105 (71); 88 (22). HRMS: calc for C22H24N4OS 392.1671; found 392.1667. 
3-Methyl-2-(methylthio)-7(S)-phenyl-6-[(S)-1-phenylethyl]-5,6,7,8-tetrahydropyrimido-
[4,5-d]pyrimidin-4(3H)-one (4g4) from 2g′ in CH3CN, benzaldehyde and (S)-camphor-10-
sulfonic acid (CSA-S). Reaction time: 15h. Colorless solid (68%). [α]D -77.2 (DCM; 25ºC; 
0,01g/l). 1H-NMR (CDCl3). δ (ppm): 1.39 (d, 6.6Hz, 3H); 2.56 (s, 3H); 3.31 (d, 17.2Hz, 1H); 
3.45 (s, 3H); 3.73 (q, 6.6Hz, 1H); 4.07 (dd, 1.9 y 17.2Hz, 1H); 4.98 (d, 3.5Hz, 1H); 5.14 (d, 
3.5Hz, 1H); 7.23-7.29 (m, 6H); 7.34-7.36 (m, 2H); 7.50-7.55 (m, 2H). 13C-NMR (CDCl3). δ 
(ppm): 14.7 p; 21.8 p; 36.9 s; 58.7 t; 69.8 t; 87.2 c; 126.5 t; 127.6 t; 128.3 t; 128.6 t; 129.0 t; 
129.7 t; 134.4 t; 142.1 q; 145.4 q; 154.9 q; 160.6 q; 160.9 q. 
3-Methyl-2-(methylthio)-7(S)-phenyl-6-((R)-1-phenylethyl)-5,6,7,8-tetrahydropyrimido[4,5-
d]pyrimidin-4(3H)-one (4g2); 3-methyl-2-(methylthio)-7(R)-phenyl-6-[(S)-1-phenylethyl]-
5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4(3H)-one (4g3) 1H-NMR (CDCl3). δ (ppm): 1.49 
(d, 6.6 Hz, 3H); 2.55 (s, 3H); 3.18 (d, 17.2 Hz, 2H); 3.39 (s, 3H); 3.80 (q, 6.6 Hz, 1H); 5.30 (d, 
3.5Hz, 1H); 5.52 (bs, 1H); 7.19-7.53 (m, 5H). 13C-NMR (CDCl3). δ (ppm): 14.7 p; 21.9 p; 29.5 
p; 39.5 s; 58.9 t; 68.4 t; 88.8 q; 126.7 t; 127.0 t; 127.3 t; 127.5 t; 127.7 t; 128.5 t; 141.6 c; 144.9 
q; 155.0 q; 160.4 q; 160.7 q. 
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Methods of calculations 
Multidimensional conformational analysis (MDCA). From the concepts of MDCA32 we 
performed a systematic conformational search for compounds 4g1-4. In such analysis the 
following variables were taken into account: 
(i) The three torsional angles 1, 2 and 3, which determine the different conformations. 
(MDCA predicts a multiplicity of 3 for the torsional angle 1 and a multiplicity of 2 for the 
torsional angles 2 and 3). 
(ii) The two possible spatial orderings for the N atom of ring B (up or down)(multiplicity 2) 
(iii) The two possible spatial orderings, axial or equatorial, for the alkyl-phenyl substituent (ring 
D) (multiplicity 2). 
(iv) The different configurational isomers due to both chiral centers (see figure 4) (multiplicity 2 
for each chiral center). 
Considering the above variables the conformational potential energy hypersurface (CPEH) might 
be raised as follow: 
 
E=E(1,2,3,up/down,ax/eq,R/S,R/S)                   (1) 
 
Equation 1 might be also expressed in function of the multiplicities as follows: 
 
E=E(3x2x2x2x2x2)=192                                          (2) 
 
Equation 2 indicates that in theory there are 192 different forms for compounds 4g1-4. However, 
our preliminary calculations indicate that the torsional angles 2 and 3 adopt only two almost 
perpendicular conformations. Considering that rings C and D are symmetrical, they give non-
identical but indistinguishable forms (energetically degenerate). Thus, Equation 2 might be 
reduced to Equation 3. 
 
E=E(3x2x2x2x2)=48                                                (3) 
 
On the basis of Equation 3 MDCA predicts 48 different forms. All these different spatial 
orderings were analyzed in our study. 
Computations. An extensive search for the low energy conformations on the PEHS was carried 
out by using a systematic search in connection with semiempirical PM6 calculations. Next to 
determine the minima on the PEHS, fully relaxed DFT optimizations were performed. 
Correlation effects were included using density functional theory (DFT) with the Beke-Lee-Yang 
Parr (B3LYP)39-41 functional and the 6-31 G(d) basis set. Minima were characterized through 
harmonic frequency analysis employing B3LYP/6-31 G(d) calculations. GIAO33-34 (gauge 
independent atomic orbital) computations were carried out using B3LYP/6-31G(d) calculations. 
All the calculations reported here were performed using the Gaussian 03 Program.35 
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From the 48 potentially available conformations of compound 4g, only 41 conformers were 
obtained for these molecules; seven conformations were annihilated during the optimization 
process. Annihilation means that they do not converge or finally converge to one of the other 41 
conformers. It should be noted that the synthesis of compound 4g1-4 was carried out from a 
particular enantiomer in the first chiral center C(1′), so that the result of the synthesis can only 
give rise to two stereoisomers R/R and R/S or S/S and S/R (C(1′)/C(7)). This assumption was 
supported by the theoretical calculations performed here. 
Considering an energetic window of 6 Kcal/mol just eight conformers were obtained for both 
diasteromers (R/R and R/S) and their equivalents (S/S and S/R) (see Table 1S and Figure 4S in 
supporting information for angles analyzed in this study). All these conformations were 
optimized at DFT level using B3LYP/6/31G(d) calculations. These conformers and their relative 
energies are summarized in Table 1S. Figure 3S shows a spatial view of the lowest-energy 
conformation obtained for compound 4g2.  
From the low-energy conformations obtained for both diasteromers R/R and R/S we calculated 
the shielding tensors using the GIAO approach33,34 from the program Gaussian 03.35 From the 
tensors we obtain the value of calculated chemical shift (calc) for each C atom of each isomer, 
using the following expression (Eq. 4): 
 
).( AImbcalc                 (4) 
  
where b and m values were obtained from the linear correlation between exp and the sum of I 
(isotropy) with A (asymmetry). Recently we demonstrated the importance to include asymmetry 
in such calculations for this type of molecule.42-43 
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